BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 19378895)

  • 1. Successful treatment with gemtuzumab ozogamicin monotherapy in a pediatric patient with resistant relapse of acute myeloid leukemia.
    Unal S; Cakir M; Kuşkonmaz B; Cetin M; Tuncer AM
    Turk J Pediatr; 2009; 51(1):69-71. PubMed ID: 19378895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.
    Roman E; Cooney E; Harrison L; Militano O; Wolownik K; Hawks R; Foley S; Satwani P; Unal E; Bhatia M; Bradley B; Del Toro G; George D; Garvin J; van de Ven C; Cairo MS
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7164s-7170s. PubMed ID: 16203817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients.
    van der Velden VH; Boeckx N; Jedema I; te Marvelde JG; Hoogeveen PG; Boogaerts M; van Dongen JJ
    Leukemia; 2004 May; 18(5):983-8. PubMed ID: 15029214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence of CD33 expression at relapse in CD33(+) acute myeloid leukaemia patients after receiving Gemtuzumab in the course of the disease.
    Chevallier P; Robillard N; Ayari S; Guillaume T; Delaunay J; Mechinaud F; Avet-Loiseau H; Mohty M; Harousseau JL; Garand R
    Br J Haematol; 2008 Dec; 143(5):744-6. PubMed ID: 19036018
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia.
    Arceci RJ; Sande J; Lange B; Shannon K; Franklin J; Hutchinson R; Vik TA; Flowers D; Aplenc R; Berger MS; Sherman ML; Smith FO; Bernstein I; Sievers EL
    Blood; 2005 Aug; 106(4):1183-8. PubMed ID: 15886328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
    Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
    Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia.
    Giles FJ
    Expert Rev Anticancer Ther; 2002 Dec; 2(6):630-40. PubMed ID: 12503209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin.
    Duong HK; Sekeres MA
    Clin Interv Aging; 2009; 4():197-205. PubMed ID: 19503782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Long-term complete remission after single therapy with gemtuzumab ozogamicin for refractory AML in an elderly patient].
    Ogura K; Machida T; Nara M; Mayama K; Akagi T; Kubo K
    Gan To Kagaku Ryoho; 2007 Nov; 34(11):1881-3. PubMed ID: 18030030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia.
    Stasi R
    Expert Opin Biol Ther; 2008 Apr; 8(4):527-40. PubMed ID: 18352855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re-administration of a combination of chemotherapy + Gemtuzumab at relapse in CD33+ AML patient allows to second remission and is feasible without extra toxicity.
    Chevallier P; Touzeau C; Ayari S; Guillaume T; Harousseau JL; Delaunay J
    Leuk Res; 2008 Aug; 32(8):1321-2. PubMed ID: 18029013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of chemotherapy and gemtuzumab ozogamicin in adult Philadelphia positive acute lymphoblastic leukemia patient harboring CD33 expression.
    Chevallier P; Mahe B; Garand R; Talmant P; Harousseau JL; Delaunay J
    Int J Hematol; 2008 Sep; 88(2):209-211. PubMed ID: 18668307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia.
    Buckwalter M; Dowell JA; Korth-Bradley J; Gorovits B; Mayer PR
    J Clin Pharmacol; 2004 Aug; 44(8):873-80. PubMed ID: 15286091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative study.
    Kobayashi Y; Tobinai K; Takeshita A; Naito K; Asai O; Dobashi N; Furusawa S; Saito K; Mitani K; Morishima Y; Ogura M; Yoshiba F; Hotta T; Bessho M; Matsuda S; Takeuchi J; Miyawaki S; Naoe T; Usui N; Ohno R
    Int J Hematol; 2009 May; 89(4):460-469. PubMed ID: 19360457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg) in children with relapsed/refractory myeloid leukemia.
    Brethon B; Auvrignon A; Galambrun C; Yakouben K; Leblanc T; Bertrand Y; Leverger G; Baruchel A
    BMC Cancer; 2006 Jun; 6():172. PubMed ID: 16805911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.
    Candoni A; Martinelli G; Toffoletti E; Chiarvesio A; Tiribelli M; Malagola M; Piccaluga PP; Michelutti A; Simeone E; Damiani D; Russo D; Fanin R
    Leuk Res; 2008 Dec; 32(12):1800-8. PubMed ID: 18621416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group.
    Taksin AL; Legrand O; Raffoux E; de Revel T; Thomas X; Contentin N; Bouabdallah R; Pautas C; Turlure P; Reman O; Gardin C; Varet B; de Botton S; Pousset F; Farhat H; Chevret S; Dombret H; Castaigne S
    Leukemia; 2007 Jan; 21(1):66-71. PubMed ID: 17051246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of gemtuzumab ozogamicin in intensive combination chemotherapy for relapsed or refractory adult acute myeloid leukemia (AML): Japan Adult Leukemia Study Group (JALSG)-AML206 study.
    Usui N; Takeshita A; Nakaseko C; Dobashi N; Fujita H; Kiyoi H; Kobayashi Y; Sakura T; Yahagi Y; Shigeno K; Ohwada C; Miyazaki Y; Ohtake S; Miyawaki S; Naoe T; Ohnishi K;
    Cancer Sci; 2011 Jul; 102(7):1358-65. PubMed ID: 21585619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful induction of molecular remission with single-agent anti-CD33 antibody (gemtuzumab ozogamicin) in chemotherapy-refractory relapse of acute myeloid leukaemia post-BMT.
    Swords R; Hayden PJ; Molloy K; Lawlor M; Browne PV; Murphy PT
    Eur J Haematol; 2004 Dec; 73(6):450-1. PubMed ID: 15522070
    [No Abstract]   [Full Text] [Related]  

  • 20. What role does gemtuzumab ozogamicin have in the treatment of acute myelogenous leukemia?
    Molnár I; Powell BL
    Curr Hematol Malig Rep; 2007 May; 2(2):104-10. PubMed ID: 20425358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.